Filing Flows › Neuraxis (NRXS) › Guidance & outlook
Neuraxis (NRXS) guidance and outlook
Neuraxis' 10-Q filed Nov 9, 2026 makes 6 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 9, 2026
- We expect to incur significant expenses and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim and RED devices and seek FDA clearance of our device for other indications.
- Our gross margin has been and will continue to be affected by a variety of factors, primarily the average selling price of our IB-Stim device, production volume, order flows, change in mix of customers, third-party manufacturing costs related to components of our devices including tariffs, and cost-reduction strategies.
- We expect our gross profit to increase for the foreseeable future as our net sales grows, both through broader insurer acceptance of our IB-Stim device in the near term and approval of our technology for the treatment of other indications over the longer term.
- We expect future R&D expenses for other indications, such as post-concussion syndrome, cyclic vomiting syndrome, post-operative pain and fibromyalgia pain.
- Our future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including…
- This additional corporate governance time required of management could limit the amount of time our management has to implement our business plan and may delay our anticipated growth plans.
Neuraxis' latest quarter
Neuraxis, Q3 2026: revenue $2.0M (+150% year over year), operating margin -324.4%, net loss $6.5M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What does Neuraxis expect?
We expect to incur significant expenses and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim and RED devices and seek FDA clearance of our device for other indications. Our gross margin has been and will continue to be affected by a variety of factors, primarily the average selling price of our IB-Stim device, production volume, order flows, change in mix of customers, third-party manufacturing costs related to components of our devices including tariffs, and cost-reduction strategies. We expect our gross profit to increase for t
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.